bPEP/bET Predicts CV Events in CKD Patients
tients with hemodialysis. 12 However, there was no study to evaluate the relationship between bPEP/bET and CV outcome in patients with CKD. The aim of this study was to investigate whether bPEP/bET is a useful predictor of CV events in patients with CKD.
Methods

Study Patients and Design
The study was conducted in a regional hospital in southern Taiwan. We consecutively enrolled 262 patients with stages 3-5 of CKD 13 from our outpatient department of internal medicine from January 2007 to May 2008. Twenty patients (7.6%) were lost to follow up for personal reasons, and a final total of 242 patients (mean age 64.5±12.8 years, 104 males/ 138 females) were included and followed until August 2009. Patients with atrial fibrillation, complete left bundle branch block, and inadequate image visualization were excluded. The protocol was approved by our Institutional Review Board and all enrolled patients gave written, informed consent.
Assessment of bPEP, bET, ABI and baPWV
The bPEP and bET were measured by using an ABI-form device, which automatically and simultaneously measures blood pressures in both arms and ankles using an oscillometric method. 10,13- 15 The bET was automatically measured from the foot to the dicrotic notch (equivalent to the incisura on the downstroke of the aortic pressure wave contour produced by the closure of aortic valve) of the pulse volume waveform. Total electromechanical systolic interval (QS2) was measured from the onset of the QRS complex on the electrocardiogram to the first high-frequency vibrations of the aortic component of the second heart sound on the phonocardiogram. The bPEP was also automatically calculated by subtracting the bET from the QS2 (Figure) . The values of ABI and brachial-ankle pulse wave velocity (baPWV) were also measured, and the measurement method has been reported and validated in previous studies. 10,14-16
Collection of Demographic, Medical and Laboratory Data
Demographic and medical data including age, gender, smoking history (ever vs never), and comorbid conditions were obtained from medical records and interviews with patients. The body mass index was calculated as the ratio of weight in kilograms divided by the square of height in meters. Laboratory data were measured from fasting blood samples using an autoanalyzer (COBAS Integra 400; Roche Diagnostics GmbH, Mannheim, Germany). Blood samples were obtained within 1 month of enrollment.
CV Events and Follow up
CV events were defined as CV death, stroke, myocardial infarction, and hospitalization for congestive heart failure. The study subjects were followed until the first episode of CV events occurred.
Statistical Analysis
Statistical analysis was performed using SPSS 12.0 for Windows (SPSS Inc, Chicago, IL, USA). Data are expressed as percentages, or mean ± standard deviation. Time to the CV events and covariates of risk factors were modeled using Cox proportional hazards model. Age, gender, and significant variables in the univariate analysis were further analyzed by multivariate analysis. A significant difference was considered when the P value less than 0.05.
Results
The differences between patients with and without CV events were shown in Table 1 . The mean age and bPEP/bET of all patients were 64.5±12.8 years and 0.36±0.09, respectively. Compared with patients without CV events, patients with CV Figure. Brachial ejection time (bET) was automatically measured from the foot to the dicrotic notch of the brachial pulse volume waveform (bPVW). Total electromechanical systolic interval (QS2) was measured from the onset of the QRS complex on the electrocardiogram (ECG) to the first high-frequency vibrations of the aortic component of the second heart sound on the phonocardiogram (PCG). The brachial pre-ejection period (bPEP) was also automatically calculated by subtracting the bET from the QS2.
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events were significantly associated with a higher prevalence of a history of diabetes mellitus (DM), a more rapid heart rate, lower bET, higher bPEP/bET, and a lower serum albumin level. In addition, there were 86 patients receiving an echocardiographic examination within 2 week of the bPEP/bET measurement. There was a significant correlation between bPEP/bET and the left ventricular ejection fraction in the 86 patients (r=-0.555, P<0.001).
The mean follow-up period was 21.0±7.3 months. Twentyeight CV events were documented during the follow-up period, including cardiac death (n=7), myocardial infarction (n=1), cerebral infarction (n=7), and hospitalization for congestive heart failure (n=13). A Cox proportional hazards regression analysis for CV mortality is shown in Table 2 . The univariate regression analysis shows that a hazard ratio (HR) of the bPEP/bET was 1.048 (95% confidence interval (CI), 1.014-1.083, P=0.005). In addition, the presence of DM, an increase in heart rate, a decrease in bET, a decrease in serum albumin level, and an increase in serum creatinine level were significantly associated with an increase in CV events. We performed 2 multivariate analyses. In the first multivariate analysis (model 1: covariates included age, gender, the presence of DM, heart rate, bET, serum albumin and creatinine levels), the presence of DM (HR, 3.359; P=0.017) and decreased serum albumin level (HR, 0.472; P=0.001) were independent predictors of CV events. In the second multivariate analysis (model 2: covariates included age, gender, the presence of DM, heart rate, bPEP/bET, serum albumin and creatinine levels), the presence of DM (HR, 3.531; P= 0.014) and the bPEP/bET (HR, 1.054; 95% CI, 1.006-1.104; P=0.026) were positively and the serum albumin level (HR, 0.525; P=0.005) was negatively associated with CV events.
The baPWV had no association with CV events in all study patients in the univariate analysis. Because in subjects with an ABI <0.9, the accuracy of baPWV was attenuated, 17 we further analyzed the 227 subjects with an ABI ≥0.9 and found that baPWV was still not associated with CV events (HR, 1.000; P=0.376). We also analyzed the correlation between ABI and CV events other than heart failure. We found that the value of ABI (per 0.1) was not associated with CV events other than heart failure in the univariate analysis (HR, 1.116; P=0.612). 
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Discussion
The present study evaluated the predictors of CV events in 242 patients with CKD and found that the bPEP/bET obtained from the ABI-form device could predict CV events. It is suggested that the bPEP/bET might be a useful predictor of CV events among CKD patients. Other factors such as the presence of DM and decreased serum albumin level were also correlated with poor CV outcomes in the study. A decrease of left ventricular systolic function was reported to predict poor CV outcomes. 7-9 An increased pre-ejection period (PEP) and shortened ejection time (ET) were reported to be correlated with impaired left ventricular systolic function. 18, 19 Hence, the ratio of PEP to ET might enhance the diagnostic value for identification of left ventricular systolic dysfunction. In fact, our previous study demonstrated that bPEP/bET had a stronger correlation with left ventricular ejection fraction than bPEP and bET. 11 In addition, our recent study also showed the bPEP/bET, but neither bPEP nor bET, was an independent predictor for CV and overall mortality in hemodialysis patients. 12 In the present study, we found that the bPEP/bET, but neither bPEP nor bET, was an independently predictor of CV events in CKD patients, which was consistent with previous findings. It implies that patients with increased bPEP/bET, a marker of left ventricular systolic dysfunction, might be a high risk group for increased CV events in patients with CKD.
Diabetes mellitus was reported to be a well-established and independent risk factor for the increased risk of CV morbidity and mortality in CKD patients, which was consistent with our findings. 1,2 In addition, malnutrition might worsen patient outcome by accelerating atherosclerosis and aggravating inflammation. 20 A low serum albumin level has been regarded as a malnutrition status. Ono et al investigated the predictor for all-cause and CV mortality in hemodialysis patients and found that a decreased serum albumin level predicted all-cause and CV mortality in hemodialysis patients. 21 Shah and Dumler also studied the correlation between serum albumin level and CV morbidity in 376 CKD patients and found that hypoalbuminaemia was an independent predictor Covariates in model 1 included: age, gender, the presence of diabetes mellitus, heart rate, bET, serum albumin and creatinine levels. Covariates in model 2 included: age, gender, the presence of diabetes mellitus, heart rate, bPEP/bET, serum albumin and creatinine levels. HR, hazard ratios; CI, confidence interval. Other abbreviations are the same as in Table 1 .
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for CV morbidity. 22 Our study demonstrated that the serum albumin level was negatively associated with CV events, which was consistent with previous findings. There are several limitations to this study. The study subjects were enrolled from only one regional hospital and thus the selection of patients was relatively limited. Therefore, generality of the results was restricted. Because comorbid conditions of our study subjects were obtained from medical records or interviews with patients, the history of heart failure could not be determined in all patients. There were 36 patients (14.9%) whose history of heart failure could not be verified. Because of the incomplete data acquisition, history of heart failure was not entered as a covariate. In addition, we did not further validate our finding with invasive methodology or non-invasive echocardiographic parameters. Finally, a complete left bundle branch block can delay the closure of the aortic valve and thus prolong QS2, so bPEP/bET can be affected by a complete left bundle branch block. Besides, the measurement of bPEP and bET during atrial fibrillation is difficult because of the beat-to-beat variation. Therefore, we excluded patients with a complete left bundle branch block and atrial fibrillation. Hence, our results can not be applied in these patients.
In conclusion, our results demonstrate that bPEP/bET can predict CV events in patients with CKD. Screening CKD patients by means of bPEP/bET might help to identify a patient group that is at a high risk group of increased CV events.
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